LENZ THERAPEUTICS ($LENZ) is expected to release its quarterly earnings data on Wednesday, March 19th after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.42 per share.
You can see Quiver Quantitative's $LENZ stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LENZ THERAPEUTICS Hedge Fund Activity
We have seen 52 institutional investors add shares of LENZ THERAPEUTICS stock to their portfolio, and 38 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 770,455 shares (+inf%) to their portfolio in Q4 2024, for an estimated $22,243,035
- PRICE T ROWE ASSOCIATES INC /MD/ added 374,326 shares (+83.4%) to their portfolio in Q4 2024, for an estimated $10,806,791
- ECOR1 CAPITAL, LLC removed 346,772 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $10,011,307
- BLACKROCK, INC. added 225,604 shares (+24.3%) to their portfolio in Q4 2024, for an estimated $6,513,187
- SAMSARA BIOCAPITAL, LLC removed 221,492 shares (-18.3%) from their portfolio in Q4 2024, for an estimated $6,394,474
- STATE STREET CORP added 205,162 shares (+71.0%) to their portfolio in Q4 2024, for an estimated $5,923,026
- PARKMAN HEALTHCARE PARTNERS LLC removed 139,357 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $4,023,236
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
LENZ THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $LENZ in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Raymond James issued a "Outperform" rating on 09/26/2024
To track analyst ratings and price targets for LENZ THERAPEUTICS, check out Quiver Quantitative's $LENZ forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
